Gastric cancer pharmacogenetics: Progress or old tripe?

Pharmacogenomics

Volumn 14, Issue 9, 2013, Pages 1053-1064

  Patel, Jai N ^a   Fuchs, Charles S ^b   Owzar, Kouros ^c   Chen, Zihua ^d   McLeod, Howard L ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Association; Cancer; Gastric; Genetic; Germline; Mutation; Pharmacogenetics; Variation

Indexed keywords

CAPECITABINE; CISPLATIN; CYTOCHROME P450 2C8; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TEGAFUR;

CANCER SURVIVAL; CYTOCHROME P450 2C8 GENE; DPD GENE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GSTM1 GENE; GSTP1 GENE; GSTT1 GENE; HAND FOOT SYNDROME; HUMAN; MTHFR GENE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; STOMACH CANCER; TREATMENT OUTCOME; UGT1A1 GENE; UGT2B7 GENE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; PHARMACOGENETICS; STOMACH NEOPLASMS;

EID: 84880469989     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.88     Document Type: Review

References (111)

1. Nishiyama M, Eguchi H. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv. Drug. Deliv. Rev. 61(5), 402-407 (2009).
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol. 12(3), 354-362 (2006).
3. MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
4. Cullinan SA, Moertel CG, Wieand HS et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J. Clin. Oncol. 12(2), 412-416 (1994).
5. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15(1), 261-267 (1997).
6. Bouche O, Raoul JL, Bonnetain F et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J. Clin. Oncol. 22(21), 4319-4328 (2004).
7. Wang F, Wang Z, Zhou N et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am. J. Clin. Oncol. 34(4), 401-405 (2011).
8. Fuchs C, Tepper J, Niedzwiecki D, Hollis D, Mamon H. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU (ECF) before and after infusion 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J. Clin. Oncol. Suppl. (2011) (Abstract 4003).
9. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36-46 (2008).
10. Kulke MH, Wu B, Clark JW et al. A Phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest. 24(3), 229-234 (2006).
11. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised Phase III noninferiority trial. Ann. Oncol. 20(4), 666-673 (2009).
12. Popov I, Radosevic-Jelic L, Jezdic S et al. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. J. BUON 13(4), 505-511 (2008).
13. Li ZY, Koh CE, Bu ZD et al. Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer. J. Surg. Oncol. 105(8), 793-799 (2012).
14. Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res. 11(10), 3778-3783 (2005).
15. Shitara K, Muro K, Ito S et al. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer. Cancer Epidemiol. Biomark. Prev. 19(5), 1311-1319 (2010).
16. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19(2), 383-386 (2001).
17. Thomas F, Hoskins JM, Dvorak A, Tan BR, McLeod HL. Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics 11(12), 1751-1756 (2010).
18. Villafranca E, Okruzhnov Y, Dominguez MA et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19(6), 1779-1786 (2001).
19. Ruzzo A, Graziano F, Kawakami K et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J. Clin. Oncol. 24(12), 1883-1891 (2006).
20. Tan BR, Thomas F, Myerson RJ et al. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J. Clin. Oncol. 29(7), 875-883 (2011).
21. Toffoli G, Cecchin E. Pharmacogenetics and stomach cancer: An update. Pharmacogenomics 8(5), 497-505 (2007).
22. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12(7), 555-558 (2002).
23. Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin. Colorectal Cancer 5(5), 359-362 (2006).
24. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer 43(6), 1011-1016 (2007).
25. van Kuilenburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin. Cancer Res. 6(12), 4705-4712 (2000).
26. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin. Cancer Res. 12(18), 5491-5495 (2006).
27. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer 45(8), 1333-1351 (2009).
28. Wilcken B, Bamforth F, Li Z et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas world wide. J. Med. Genet. 40(8), 619-625 (2003).
29. Lu JW, Gao CM, Wu JZ, Sun XF, Wang L, Feng JF. Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma. Ai Zheng 23(8), 958-962 (2004).
30. Ott K, Vogelsang H, Marton N et al. The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int. J. Cancer 119(12), 2885-2894 (2006).
31. Shim HJ, Yun JY, Hwang JE et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 101(5), 1247-1254 (2010).
32. Goekkurt E, Al-Batran SE, Hartmann JT et al. Pharmacogenetic analyses of a Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: A study of the arbeitsgemeinschaft internistische onkologie. J. Clin. Oncol. 27(17), 2863-2873 (2009).
33. Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res. 62(12), 3361-3364 (2002).
34. Largillier R, Etienne-Grimaldi MC, Formento JL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res. 12(18), 5496-5502 (2006).
35. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40(7), 939-950 (2004).
36. Caronia D, Martin M, Sastre J et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin. Cancer Res. 17(7), 2006-2013 (2011).
37. Park SR, Kong SY, Nam BH et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br. J. Cancer 104(7), 1126-1134 (2011).
38. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin. Cancer Res. 14(1), 8-13 (2008).
39. Fujita K, Yamamoto W, Endo S et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci. 99(5), 1049-1054 (2008).
40. Goekkurt E, Hoehn S, Wolschke C et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 94(2), 281-286 (2006).
41. Bradbury PA, Kulke MH, Heist RS et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet. Genomics 19(8), 613-625 (2009).
42. Buchanan CC, Torstenson ES, Bush WS, Ritchie MD. A comparison of cataloged variation between International HapMap Consortium and 1000 Genomes Project data. J. Am. Med. Inform. Assoc. 19(2), 289-294 (2012).
43. Tse D, Zhai R, Zhou W et al. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control 19(10), 1077-1083 (2008).
44. Innocenti F, Liu W, Fackenthal D et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP- glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics 18(8), 683-697 (2008).
45. Parmar S, Stingl JC, Huber-Wechselberger A et al. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Res. 13(3), R57 (2011).
46. Gehrmann M, Schmidt M, Brase JC, Roos P, Hengstler JG. Prediction of paclitaxel resistance in breast cancer: Is CYP1B1*3 a new factor of influence? Pharmacogenomics 9(7), 969-974 (2008).
47. Marsh S, Somlo G, Li X et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7(5), 362-365 (2007).
48. Dai D, Zeldin DC, Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597-607 (2001).
49. Leskela S, Jara C, Leandro-Garcia LJ et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 11(2), 121-129 (2011).
50. Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol. 20(2), 272-277 (2009).
51. Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol. Rep. 23(1), 271-278 (2010).
52. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: Are we there yet? Pharmacotherapy 28(6), 755-768 (2008).
53. Satoh T, Ura T, Yamada Y et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1. *28 and/or UGT1A1.*6 polymorphisms. Cancer Sci. 102(10), 1868-1873 (2011).
54. Wang Y, Shen L, Xu N et al. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J. Gastroenterol. 18(45), 6635-6644 (2012).
55. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1. *28 genotype and irinotecan-induced neutropenia: Dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007).
56. Marcuello E, Paez D, Pare L et al. A genotype-directed Phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br. J. Cancer 105(1), 53-57 (2011).
57. Jo JC, Lee JL, Ryu MH et al. Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br. J. Cancer 106(10), 1591-1597 (2012).
58. Font A, Salazar R, Maurel J et al. Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: A Phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemother. Pharmacol. 62(6), 1075-1083 (2008).
59. Park SR, Kong SY, Rhee J et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: Clinical and pharmacogenetic results. Ann. Oncol. 22(4), 890-896 (2011).
60. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: Current management and new treatment developments. Drugs 68(3), 299-317 (2008).
61. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. [see comment]. J. Clin. Oncol. 20(8), 1996-2004 (2002).
62. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. [see comment]. J. Clin. Oncol. 15(1), 261-267 (1997).
63. Ajani JA, Van Custem E, Moiseyenko FC. Docetaxel (D), cisplatin, 5-fluorouracil compared with cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma: Interim results of a randomized Phase III trial (V 325). Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 999).
64. Ridwelski K, Gebauer T, Fahlke J et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol. 12(1), 47-51 (2001).
65. Roth AD, Maibach R, Martinelli G et al. Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann. Oncol. 11(3), 301-306 (2000).
66. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85(2), 295-301 (1999).
67. Kollmannsberger C, Quietzsch D, Haag C et al. A Phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br. J. Cancer 83(4), 458-462 (2000).
68. Ajani JA, Baker J, Pisters PW et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 16(5 Suppl. 5), S16-S18 (2002).
69. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 17(1), 319-323 (1999).
70. Lim WT, Lim ST, Wong NS, Koo WH. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians. J. Chemother. 15(4), 400-405 (2003).
71. Pozzo C, Bugat R, Peschel C. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: Final results of a randomized Phase II study. Proc. Am. Soc. Clin. Oncol. 21 (2001) (Abstract 531a).
72. Ohtsu A, Shimada Y, Shirao K et al. Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 21(1), 54-59 (2003).
73. Dank M, Zaluski J, Barone C et al. Randomized Phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. Proc. Am. Soc. Clin. Oncol. 24 (2005) (Abstract 4003).
74. Al-Batran SE, Atmaca A, Hegewisch-Becker S et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. 22(4), 658-663 (2004).
75. de Vita F, Orditura M, Matano E et al. A Phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br. J. Cancer 92(9), 1644-1649 (2005).
76. Kim DY, Kim JH, Lee SH et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann. Oncol. 14(3), 383-387 (2003).
77. Louvet C, Andre T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 20(23), 4543-4548 (2002).
78. Souglakos J, Syrigos K, Potamianou A et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: A multicentre Phase II trial. Ann. Oncol. 15(8), 1204-1209 (2004).
79. Koizumi W, Tanabe S, Azuma M et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int. J. Cancer 126(1), 162-170 (2010).
80. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF. Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J. Hum. Genet. 51(3), 155-160 (2006).
81. Ichikawa W, Takahashi T, Suto K et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int. J. Cancer 119(8), 1927-1933 (2006).
82. Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest. 24(3), 235-241 (2006).
83. Takiuchi H, Kawabe S, Gotoh M, Katsu K. Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointest. Cancer Res. 1(5), 171-176 (2007).
84. Hua D, Huang ZH, Mao Y, Deng JZ. Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J. Gastroenterol. 13(37), 5030-5034 (2007).
85. Seo BG, Kwon HC, Oh SY et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol. Rep. 22(1), 127-136 (2009).
86. Kim SH, Kwon HC, Oh SY et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/ oxaliplatin chemotherapy in advanced colorectal cancer. Am. J. Clin. Oncol. 32(1), 38-43 (2009).
87. Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbeck's Arch. Surg. 395(3), 217-225 (2010).
88. Huang ZH, Hua D, Li LH. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Cancer Chem. Pharmacol. 63(5), 911-918 (2009).
89. Harpole DH Jr, Moore MB, Herndon JE 2nd et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res. 7(3), 562-569 (2001).
90. Cui YH, Liu TS, Zhuang RY et al. Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J. Dig Dis. 10(2), 118-123 (2009).
91. Keam B, Im SA, Han SW et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 27(8), 148-157 (2008).
92. Jakobsen A, Nielsen JN, Gyldenkerne N et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol. 23(7), 1365-1369 (2005).
93. Han SW, Oh DY, Im SA et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci. 101(3), 793-799 (2010).
94. Toriumi F, Kubota T, Saikawa Y et al. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res. 24(4), 2455-2463 (2004).
95. Kwon HC, Roh MS, Oh SY et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol. 18(3), 504-509 (2007).
96. Kim KH, Kwon HC, Oh SY et al. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 16(1), 74-82 (2011).
97. Peng RJ, Dong QM, Shi YX et al. Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients. Ai Zheng 25(8), 1039-1043 (2006).
98. Zhang H, Li YM, Zhang H, Jin X. DPY.D. *5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: Results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med. Oncol. 24(2), 251-258 (2007).
99. Matsubara J, Nishina T, Yamada Y et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br. J. Cancer 98(4), 832-839 (2008).
100. Grau JJ, Caballero M, Monzo M et al. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J. Surg. Oncol. 98(2), 130-134 (2008).
101. Koizumi W, Okayasu I, Hyodo I, Sakamoto J, Kojima H, Clinical Study Group of C. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs 19(8), 819-824 (2008).
102. Zhang XP, Bai ZB, Chen BA et al. Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population. Chin. Med. J. 125(5), 741-746 (2012).
103. Jeung HC, Rha SY, Shin SJ et al. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anticancer Drugs 22(8), 801-810 (2011).
104. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment. Pharmacogenomics 10(6), 931-944 (2009).
105. Kong SY, Lim HS, Nam BH et al. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics 10(7), 1147-1155 (2009).
106. Okuyama T, Maehara Y, Endo K et al. Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 74(4), 1230-1236 (1994).
107. Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 94(12), 936-942 (2002).
108. Ott K, Rachakonda PS, Panzram B et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann. Surg. Oncol. 18(9), 2688-2698 (2011).
109. Warnecke-Eberz U, Vallbohmer D, Alakus H et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J. Gastrointest. Surg. 13(8), 1411-1421 (2009).
110. Liu YP, Ling Y, Zhang YP, Liu BR. Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy. Zhonghua Yi Xue Za Zhi 91(4), 256-259 (2011).
111. Shitara K, Matsuo K, Ito S et al. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac. J. Cancer Prev. 11(2), 447-452 (2010).